Table 6.

Prognostication of survival scores in patients with spinal metastases

Score (risk groups)	Multiple myeloma excluded						Multiple myeloma included
	N	Median	95% CI	Mean	95% CI	P	N	Median	95% CI	Mean	95% CI	P
Tokukashi						0.051						0.002*
Palliative	15	5	2–8	12	4–20		15	5	2–8	12	4–20
Indifferent	30	11	6–16	14	9–18		34	13	9–17	17	11–23
Excisional	14	14	0–42	46	21–71		20	56	12–100	53	31–76
Tokuhashi revised						0.008*						0.005*
No surgery	26	4	2–6	11	6–17		28	4	1–7	15	8–21
Palliative	26	14	11–17	18	12–23		30	14	12–16	22	14–30
Excisional	7	nd		60	26–95		11	56	10–102	58	29–87
Tomita						0.005*						<0.001*
Long-term	19	17	3–30	46	24–69		27	56	0–120	54	35–73
Mid-term	13	19	9–29	20	12–28		14	19	8–29	23	14–31
Palliative	12	6	4–9	9	5–14		13	7	6–9	10	6–14
Supportive	15	3	0–5	10	3–17		15	3	0–5	10	3–17
Van der Linden**						0.014*						0.002*
A (bad)	48	8	5–10	14	10–18		50	9	5–12	15	11–20
B (middle)	11	24	13–35	48	17–79		17	24	0–70	52	29–74
C (surgery)	0	nd	nd	nd	nd		2	nd	nd	nd	nd
Sioutos						0.584						0.364
Excision	40	10	6–15	23	12–34		49	14	7–21	30	18–42
Palliative	19	7	3–11	16	8–24		20	7	2–12	19	10–27
Bauer						<0.001*						<0.001*
Bad	9	2	2–3	3	1–5		9	2	2–3	3	1–5
Intermediate	34	10	6–14	15	10–21		39	10	5–15	18	13–24
Good	16	21	10–31	46	23–68		21	56	9–103	51	31–72
Bauer modified						<0.001*						<0.001*
No surgery	14	3	0–5	7	1–13		14	3	0–5	7	1–13
Dorsal	20	9	3–14	13	8–18		22	10	2–18	15	10–20
Ventral-dorsal	25	17	7–26	40	22–59		33	30	12–48	48	31–64

Log-rank test

* Significant at P < 0.05

** Only two censored multiple myeloma patients in group C

n number of patients, 95% CI 95% confidence interval, mean/median survival period (months), nd not done